tradingkey.logo

Journey Medical Corp

DERM
View Detailed Chart

7.300USD

+0.030+0.41%
Close 09/19, 16:00ETQuotes delayed by 15 min
171.34MMarket Cap
LossP/E TTM

Journey Medical Corp

7.300

+0.030+0.41%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.41%

5 Days

+2.67%

1 Month

+3.25%

6 Months

+26.96%

Year to Date

+86.70%

1 Year

+43.70%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
71 / 175
Overall Ranking
215 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
11.800
Target Price
+62.31%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.13M.
Undervalued
The company’s latest PE is -19.92, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 10.34M shares, increasing 0.52% quarter-over-quarter.
Held by Wasatch Global Investors
Star Investor Wasatch Global Investors holds 1.15M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.31.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.
Ticker SymbolDERM
CompanyJourney Medical Corp
CEOMr. Claude Maraoui
Websitehttps://journeymedicalcorp.com/
KeyAI